Rise Mitchell
Psychiatric/Mental Health · Omaha, NENPI 1639503816
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,549 of the $4,537 with a category attached, or 78.2%. 25 manufacturers reported payments, led by Johnson & Johnson at 29.7% of the total. Reporting peaked in 2024 at $2,026 and has fallen 93.2% since, to $137 in 2025.
Across 191 payments — averaging $23.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$689
- AbbVie$487
- Axsome Therapeutics, Inc.$282
- Lundbeck LLC$208
- Takeda Pharmaceuticals U.S.A., Inc.$202
- plus $1K from 19 others
What the payments were for
- Travel & lodging$96521%
- Food & beverage$3,54978%
- Education$231%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$1,247
- INVEGA TRINZA$140
- VRAYLAR$125
- CAPLYTA$125
- Auvelity$121
How this compares
$4,537 in reported general payments places this provider in the 80th percentile of 255 psychiatric/mental health providers in Nebraska.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AplenzinBupropion Hbr | 12 | $22,755 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 12 | $341 |
| Duloxetine Hcl | 13 | $286 |
| Clonazepam | 15 | $153 |
| Trazodone Hcl | 13 | $121 |
| Alprazolam | 16 | $26 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch Health US, LLCAplenzin | $69 | $22,75512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 255 psychiatric/mental health providers in Nebraska.
Other psychiatric/mental health in Omaha
- Janelle HillOmaha$24K
- Kristi BoseOmaha$13K
- Robert LundholmOmaha$12K
- Virginia SmithOmaha$11K
- Christina HadleyOmaha$11K
- Julie ZulkoskyOmaha$8K
- John RamseyOmaha$8K
- M Joyce SasseOmaha$7K
- Molly PetersenOmaha$6K
- Salina AndersonOmaha$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.